Population Group
Philips and AWS Strengthen Strategic AI Partnership, Expanding Cloud-Enabled Diagnostics to Europe
Philips, AWS, Strategic AI Collaboration, Cloud-Enabled Diagnostics, European Expansion, Healthcare Innovation, Integrated Diagnostics Portfolio, Generative AI Applications
Citizen Health Secures $14.5M in Seed Funding to Revolutionize Rare Disease Care with AI-Powered Data Platform
Citizen Health, Rare Disease Care, AI-Powered Data Platform, Seed Funding, Chan Zuckerberg Initiative, Personalized Healthcare
FDA Raises Sterility and Quality Concerns at Mark Cuban’s Dallas Drug Compounding Facility
Mark Cuban, Cost Plus Drugs, FDA, sterility concerns, quality issues, drug compounding, Dallas facility
European Commission Imposes €463 Million Fine on Teva for Anti-Competitive Practices in MS Drug Market
Teva, European Commission, fine, MS drug, competition tactics, Copaxone, market dominance
Astellas Withdraws European Application for Geographic Atrophy Treatment Izervay
Astellas, Izervay, geographic atrophy, European application withdrawal, avacincaptad pegol
Icon, Irish CRO Giant, Announces Layoffs Following Disappointing Q3 Performance
Icon, layoffs, Q3 performance, Irish CRO, biotech industry
Merck’s KEYTRUDA Receives 30th European Approval for Gynecologic Cancers
KEYTRUDA, pembrolizumab, European Commission, gynecologic cancers, endometrial cancer, cervical cancer, cancer treatment, immunotherapy.
Starboard Value Targets Kenvue for Revitalization Following $1B Stake in Pfizer
Starboard Value, Kenvue, Johnson & Johnson, Pfizer, activist investor, consumer health, pharmaceuticals
European Commission’s Reconsideration of Translarna’s Marketing Authorization: A Critical Turning Point for Duchenne Muscular Dystrophy Treatment
Translarna, Duchenne muscular dystrophy, European Commission, EMA, CHMP, conditional marketing authorization, drug approval, regulatory decisions
Pfizer Secures EU Approval for TALZENNA in Combination with XTANDI for Metastatic Castration-Resistant Prostate Cancer
TALZENNA, XTANDI, metastatic castration-resistant prostate cancer (mCRPC), PARP inhibitor, European Commission approval, prostate cancer treatment.